Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 19/20 | 1.00 |
| ▸ | MMP9 | P14780 | 19/20 | 1.00 |
| ▸ | MMP14 | P50281 | 14/20 | 1.00 |
| ▸ | MMP8 | P22894 | 10/20 | 1.00 |
| ▸ | MMP3 | P08254 | 6/20 | 0.75 |
| ▸ | MMP7 | P09237 | 4/20 | 0.75 |
| ▸ | MMP1 | P03956 | 1/20 | 0.72 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17039275 | 1.00 | MMP2 (1.00) | MMP2MMP9MMP14MMP8MMP3 | |
| SCHEMBL19087061 | 1.00 | MMP2 (1.00) | MMP2MMP9MMP14MMP8MMP3 | |
| Hydrochloric Acid SCHEMBL29394935 | 0.99 | MMP2 (1.00) | MMP2MMP9MMP14MMP8MMP3 | |
| Hydrochloric Acid SCHEMBL30582480 | 0.99 | MMP2 (1.00) | MMP2MMP9MMP14MMP8MMP3 | |
| Hydrochloric Acid SCHEMBL30582481 | 0.99 | MMP2 (1.00) | MMP2MMP9MMP14MMP8MMP3 | |
| SCHEMBL10187466 | 0.86 | MMP2 (0.75) | MMP2MMP9MMP14MMP8MMP3 | |
| SCHEMBL17039212 | 0.86 | MMP2 (0.75) | MMP2MMP9MMP14MMP8MMP3 | |
| SCHEMBL10187460 | 0.86 | MMP2 (1.00) | MMP2MMP9MMP14MMP8MMP3 | |
| SCHEMBL12290723 | 0.85 | MMP2 (1.00) | MMP2MMP9MMP14MMP8MMP3 | |
| Hydrochloric Acid SCHEMBL14716993 | 0.84 | MMP2 (1.00) | MMP2MMP9MMP14MMP8MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10357546-B2 | Acceleration of diabetic wound healing | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2019-07-23 | — | — | US | disclosed |
| US-10253013-B2 | Selective matrix metalloproteinase inhibitors | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2019-04-09 | — | — | US | disclosed |
| US-9951035-B2 | Selective matrix metalloproteinase inhibitors | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951035-B2 | Selective matrix metalloproteinase inhibitors | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170274053-A1 | ACCELERATION OF DIABETIC WOUND HEALING | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170274053-A1 | ACCELERATION OF DIABETIC WOUND HEALING | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170190685-A1 | SELECTIVE MATRIX METALLOPROTEINASE INHIBITORS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170190685-A1 | SELECTIVE MATRIX METALLOPROTEINASE INHIBITORS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2017-07-06 | — | — | US | disclosed |
| US-9604957-B2 | Selective matrix metalloproteinase inhibitors | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2017-03-28 | — | — | US | disclosed |
| US-9604957-B2 | Selective matrix metalloproteinase inhibitors | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2017-03-28 | — | — | US | disclosed |
| US-20170015647-A1 | SELECTIVE MATRIX METALLOPROTEINASE INHIBITORS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2017-01-19 | — | — | US | disclosed |
| US-20170015647-A1 | SELECTIVE MATRIX METALLOPROTEINASE INHIBITORS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2017-01-19 | — | — | US | disclosed |
| WO-2016044844-A1 | ACCELERATION OF DIABETIC WOUND HEALING | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2016-03-24 | — | — | WO | disclosed |
| WO-2015127302-A1 | SELECTIVE MATRIX METALLOPROTEINASE INHIBITORS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2015-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253013-B2 | Selective matrix metalloproteinase inhibitors | MMP14, MMP9, MMP13 | MMP2 14/4885MMP9 2/4885MMP14 1/4885 |
| US-20170274053-A1 | ACCELERATION OF DIABETIC WOUND HEALING | MMP8, MMP9, MMP1 | MMP2 6/4885MMP9 2/4885MMP14 13/4885 |
| US-20170190685-A1 | SELECTIVE MATRIX METALLOPROTEINASE INHIBITORS | MMP14, MMP9, MMP13 | MMP2 14/4885MMP9 2/4885MMP14 1/4885 |
| US-20170015647-A1 | SELECTIVE MATRIX METALLOPROTEINASE INHIBITORS | MMP14, MMP9, MMP13 | MMP2 14/4885MMP9 2/4885MMP14 1/4885 |
| US-10357546-B2 | Acceleration of diabetic wound healing | MMP8, MMP9, MMP1 | MMP2 6/4885MMP9 2/4885MMP14 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.